AC Omega3.

Trial name or title	The Aboriginal cardiovascular omega‐3 randomised controlled trial (AC Omega3)
Methods	RCT
Participants	Indigenous Australian adults with stable coronary artery disease
Interventions	Each for 12 months: Arm 1: omega‐3 (1800 mg/d AlaskOmega: 3 capsules/d: 400 mg EPA and 200 mg DHA) Arm 2: placebo mixed oil capsules (1000 mg/d: 3 capsules/d containing palm oil, gelatin, glycerol, sunflower oil, rapeseed oil, mixed tocopherols, and a "small amount" of fish oil ((or taste) to aid blinding)
Outcomes	Primary: serum non‐HDL cholesterol Secondary: triglycerides, total cholesterol, LDL, HDL, lipid functionality by cholesterol efflux and CETP, heart rate variability, platelet function and thrombosis markers, inflammation markers, cumulative combined rate of major adverse cardiac events (including death, non‐fatal MI, unstable angina, non‐fatal stroke, revascularisation and cardiac‐related hospital admissions)
Starting date	Registered on Trials Registry: 10 July 2014 Trial start date: 1 October 2014 Trial completion date est: unclear
Contact information	Alex Brown (PI), Wardliparingga Aboriginal Unit, Adelaide, Australia, alex.brown@sahmri.com
Notes	ACTRN12614000732684 Alex Brown contacted in 2016: confirmed trial is actively recruiting